Granules India is currently trading at Rs. 121.95, up by 1.95 points or 1.63% from its previous closing of Rs. 120.00 on the BSE.
The scrip opened at Rs. 123.35 and has touched a high and low of Rs. 125.60 and Rs. 121.20 respectively. So far 3,64,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 164.45 on 01-Dec-2015 and a 52 week low of Rs. 101.25 on 12-Feb-2016.
Last one week high and low of the scrip stood at Rs. 125.60 and Rs. 117.75 respectively. The current market cap of the company is Rs. 2,648.29 crore.
The promoters holding in the company stood at 51.04%, while Institutions and Non-Institutions held 9.09% and 39.87% respectively.
Granules India’s Gagillapur facility located at Hyderabad in state of Telangana, has successfully completed US Food and Drug Administration (USFDA) inspection without any observations. This facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).
The company has recently received approval from USFDA for anti-inflammatory drug Ibuprofen tablets in the US market. The regulator has approved Abbreviated New Drug Application (ANDA) for Ibuprofen tablets USP, 200 mg (OTC) filed by the pharma major.
Granules India produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.05 |
Dr. Reddys Lab | 1354.20 |
Cipla | 1470.05 |
Lupin | 2190.50 |
Zydus Lifesciences | 1004.05 |
View more.. |